Viva Biotech sells 24% stake in CRO business Viva Shanghai for $150m
Viva Biotech Holdings Group has announced the fundraising of nearly $150 million by transferring about 24% of its equity interest in Viva Shanghai, its chief ... Read More
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More